首页> 美国卫生研究院文献>Oncotarget >Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes
【2h】

Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes

机译:使用靶向光学/ MRI双模态探针对肝癌进行肿瘤学成像

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The accurate preoperative detection and intraoperative navigation afforded by imaging techniques have had significant impact on the success of liver cancer surgeries. However, it is difficult to achieve satisfactory performance in both diagnosis and surgical treatment processes using any single modality imaging method. Here, we report the synthesis and characteristics of a novel dual-modality magnetic resonance imaging (MRI) and near-infrared fluorescence (NIRF) probe and verify its feasibility in nude mouse models with liver cancer. The probes are comprised of superparamagnetic iron oxide (SPIO) nanoparticles coated with liposomes to which a tumor-targeted agent, Arg-Gly-Asp peptides (RGD), and a NIRF dye (indocyanine green, ICG) have been conjugated. Specific targeting, biodistribution, and the imaging ability of the probes for MRI-NIRF were examined. Furthermore, we applied the dual-modality methodology toward the preoperative diagnosis and intraoperative guidance of radical resection in mouse models with both orthotopic liver tumors and intrahepatic tumor metastasis. The study demonstrated that both MRI and fluorescent images showed clear tumor delineation after probe injection (SPIO@Liposome-ICG-RGD). The contrast-to-noise ratio obtained from MRI was 31.9 ± 25.4 at post-injection for the preoperative diagnosis, which is helpful for detecting small tumors (0.9 ± 0.5 mm). The maximum tumor to background ratio of NIRF imaging was 2.5 ± 0.3 at 72 h post-injection for effectively capturing miniscule tumor lesions (0.6 ± 0.3 mm) intraoperatively. The novel MRI-NIRF dual modality probes are promising for the achievement of more accurate liver tumor detection and resection.
机译:成像技术所提供的准确的术前检测和术中导航对肝癌手术的成功具有重大影响。但是,使用任何一种单模态成像方法都难以在诊断和外科治疗过程中均获得令人满意的性能。在这里,我们报告新型双模态磁共振成像(MRI)和近红外荧光(NIRF)探针的合成和特征,并验证其在患有肝癌的裸鼠模型中的可行性。探针由涂有脂质体的超顺磁性氧化铁(SPIO)纳米颗粒组成,脂质体上已缀合了肿瘤靶向药物,Arg-Gly-Asp肽(RGD)和NIRF染料(吲哚菁绿,ICG)。检查了针对MRI-NIRF的特异性靶向,生物分布和成像能力。此外,我们将双模式方法应用于具有原位肝肿瘤和肝内肿瘤转移的小鼠模型的术前诊断和根治性切除术的术中指导。这项研究表明,在注射探针(SPIO @脂质体-ICG-RGD)后,MRI和荧光图像均显示出清晰的肿瘤轮廓。注射后通过MRI获得的对比度噪声比为31.9±25.4,可用于术前诊断,这有助于检测小肿瘤(0.9±0.5 mm)。注射后72小时,NIRF成像的最大肿瘤与背景比率为2.5±0.3,以有效地捕获术中的微小肿瘤病变(0.6±0.3 mm)。新型MRI-NIRF双模态探针有望实现更准确的肝肿瘤检测和切除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号